Pharmacokinetics of esomeprazole following varying intravenous administration rates

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 6, 2005, Pages 351-354

  Niazi, Mohammad ^a   Ahlbom, Henrik ^a   Bondarov, Patrik ^a   Karlsson, Anna H ^a   Hassan Alin, Mohammed ^a   Rydholm, Hans ^a   Röhss, Kerstin ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; INFUSION RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE;

ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OMEPRAZOLE; PROTON PUMPS;

EID: 29744468594     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_150.x     Document Type: Article

References (19)

1. Andersson, T., M. Hassan-Alin, G. Hasselgren, K. Rohss & L. Weidolf: Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokin. 2001a, 40, 411-426.
2. Andersson, T., K. Rohss, E. Bredberg & M. Hassan-Alin: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Therap. 2001b, 15, 1563-1569.
3. Chua, R. T., H. J. Lin, K. Wang, C. L. Perng, W. C. Lo, C. H. Lee & S. D. Lee: Intravenous omeprazole prevents rebleeding in peptide ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei) 1996, 57, 139-145.
4. DiPalma, J. A.: Management of severe gastroesophageal reflux disease. J. Clin. Gastroenterol. 2001, 32, 19-26.
5. Geus, W. P.: Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand. J. Gastroenterol. 2000, 232, 10-20.
6. Hassan-Alin, M., T. Andersson, E. Bredberg & K. Rohss: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. 2000, 56, 665-670.
7. Hunt, R. H.: The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 1995, 9, 3-7.
8. Lagerström, P. O. & B. A. Persson: Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J. Chromatogr. 1984, 309, 347-356.
9. Lind, T., L. Rydberg, A. Kyleback, A. Jonsson, T. Andersson, G. Hasselgren, J. Holmberg & K. Rohss: Esoomeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 2000, 14, 861-867.
10. Miner, P., Jr. P. O. Katz, Y. Chen & M. V. Sostek: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Amer. J. Gastroenterol. 2003, 98, 2616-2620.
11. Newton, M., M. A. Kamm, T. Quigley & W. R. Burnham: Symptomatic gastroesophageal reflux in acutely hospitalized patients. Dig. Dis. Sci. 1999, 44, 140-148.
12. Röhss, K., P. Bondarov, C. Lundin, C. Nilsson-Pieschl & L. Nyman: Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects. Gastroenterology 2003,124 (Suppl. 1), A231.
13. Röhss, K., T. Lind & C. Wilder-Smith: Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg, in patients with gastroesophageal reflux symptoms. Eur. J. Clin. Pharmacol. 2004, 60, 531-539.
14. Schindlbeck, N. E., C. Heinrich, A. Konig, A. Dendorfer, F. Pace & S. A. Muller-Lissner: Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology 1987, 93, 85-90.
15. Schneider, H., C. J. van Rensburg & S. Schmidt: Esomeprazole 40 mg provides safe and effective healing of erosive esophagitis whether administered as an intravenous (IV) injection, an infusion or orally. Amer. J. Gastroenterol. 2003, 98 (Suppl. 1), S11.
16. Tripathi, A., M. Somwanshi, B. Singh & P. Bajaj: A comparison of intravenous ranitidine and omeprazole on gastric volume and pH in women undergoing emergency caesarean section. Can. J. Anaesth. 1995, 42, 797-800.
17. Vinayek, R., H. Frucht, J. F. London, L. S. Miller, H. A. Stark, J. A. Norton, C. Cederberg, R. T. Jensen, J. D. Gardner & P. N. Maton: Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990, 99, 10-16.
18. Wilder-Smith, C., K. Röhss, P. Bondarov, C. Lundin & C. Nilsson-Pieschl: Esomeprazole 40 mg administered intravenously (IV) as a 3-min. injection or 30-min. infusion provides the same effective acid control in healthy subjects. Gastroenterology 2003a, 124, A233.
19. Wilder-Smith, C., P. Bondarov, B. Hallerbäck, C. Nilsson-Pieschl, H. Ahlbom & K. Röhss: Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days. Amer. J. Gastroenterol. 2003b, 98 (Suppl. 1), S24-S25.